Evolus (EOLS) Income from Continuing Operations (2017 - 2026)
Evolus' (EOLS) quarterly Income from Continuing Operations came in at 10674000.0 in Q1 2026, up 43.5% YoY from 7438333.01 in Q1 2025, and down 8310.77% on a QoQ basis from 130000.0 in Q4 2025.
Evolus (EOLS) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Income from Continuing Operations data on file, last reported at 10674000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 43.5% year-over-year to 10674000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43423000.0 (up 22.74% YoY) and the FY2025 annual result came in at 51641000.0, down 2.42% from the prior year.
- Income from Continuing Operations retreated to 10674000.0 in Q1 2026, from 130000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 130000.0 in Q4 2025 to a low of 23471000.0 in Q2 2022.
- A 5-year average of 14637176.47 and a median of 15737000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 373.41% — and 2025, when it soared 101.91%.
- Tracing EOLS's Income from Continuing Operations over 5 years: stood at 13164000.0 in 2022, then rose by 10.13% to 11831000.0 in 2023, then jumped by 42.6% to 6791000.0 in 2024, then surged by 101.91% to 130000.0 in 2025, then slumped by 8310.77% to 10674000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 10674000.0 (Q1 2026), 130000.0 (Q4 2025), and 15737000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | -8.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.05 Mn |
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -17.14 Mn |
| Mar 31, 2025 | -18.89 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -14.79 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -23.47 Mn |
| Mar 31, 2022 | -17.50 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -19.43 Mn |